leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...112113114115116117118119120121122...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., paclitaxel / Generic mfg.
    Safety and efficacy of intraperitoneal paclitaxel plus systemic FOLFOX for gastric cancer with peritoneal metastasis: Phase I results. (Live Stream | Level 1, West Hall; Online Only) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_97;    
    P1/2
    This study was designed as a dose-escalation study of intraperitoneal (IP) paclitaxel combined with intravenous (IV) fluorouracil, leucovorin, and oxaliplatin (FOLFOX) to determine the recommended phase II dose in gastric cancer patients. The biweekly regimen of IP paclitaxel and FOLFOX is safe and the recommended dose for a phase II trial is 60mg/m2.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial completion date, Trial primary completion date, Metastases:  FIRE-4: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (clinicaltrials.gov) -  Dec 3, 2021   
    P3,  N=550, Recruiting, 
    FOLFOX-A has a significant response rate, expected toxicities, and should be considered for future investigation in combination with immunotherapy given the recent approvals. Trial completion date: Mar 2022 --> Dec 2024 | Trial primary completion date: Mar 2020 --> Dec 2022
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
    Enrollment closed, Metastases:  FIRE-4.5: FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (clinicaltrials.gov) -  Dec 3, 2021   
    P2,  N=109, Active, not recruiting, 
    Trial completion date: Mar 2022 --> Dec 2024 | Trial primary completion date: Mar 2020 --> Dec 2022 Recruiting --> Active, not recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  LIPEMIA RETINALIS DURING CHEMOTHERAPY WITH ADJUNCTIVE GLUCOCORTICOID TREATMENT IN A PATIENT WITH COLON CARCINOMA. (Pubmed Central) -  Dec 2, 2021   
    Lipemia retinalis associated with visual impairment may occur during chemotherapy under accompanying treatment with dexamethasone. Even if patients with hyperlipidemia are metabolically well-controlled with oral medication, treatment with dexamethasone can potentially lead to decompensation of hyperlipidemia causing secondary lipemia retinalis.
  • ||||||||||  irinotecan / Generic mfg.
    Clinical, Review, Journal:  Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. (Pubmed Central) -  Dec 2, 2021   
    It is in this second line setting where Aflibercept offers an alternative and effective therapeutic option, thought its specific mechanism of action for different patient's profile: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientific evidence focused on Aflibercept as an alternative treatment.
  • ||||||||||  pegvorhyaluronidase alfa (PEGPH20) / Halozyme
    Trial completion date, Metastases:  S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Dec 1, 2021   
    P1/2,  N=126, Active, not recruiting, 
    Administration of mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients refractory to gemcitabine-based chemotherapy resulted in increased survival rates than S-1 treatment alone. Trial completion date: Oct 2021 --> Jul 2022
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Clinical, Review, Journal:  Advances and challenges of neoadjuvant therapy in pancreatic cancer. (Pubmed Central) -  Dec 1, 2021   
    A variety of chemotherapy regimens were tried for neoadjuvant therapy in pancreatic cancer, and FOLFIRINOX and Nab-Paclitaxel plus Gemcitabine are two preferred regimens at present...Based on new findings of the remarkable performance of several chemotherapy regimens with or without radiotherapy, the neoadjuvant indications of pancreatic cancer have extended in recent years. However, it is still a challenge to assess the neoadjuvant treatment response and determine the timing of surgery.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal:  Effectiveness of adjuvant FOLFOX versus 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach. (Pubmed Central) -  Nov 29, 2021   
    Conclusions The combination of veliparib and FOLFOX was safe for patients with metastatic PDAC and showed promising activity particularly in patients with platinum-naive disease that harbors a pathogenic HR-DDR mutation. This study supports mounting evidence of little to no incremental reduction in five-year mortality for FOLFOX versus 5FU in older adults with stage II-III colon cancer, emphasizing the importance of combining clinical trial and real-world data to support such conclusions.
  • ||||||||||  leucovorin calcium / Generic mfg., sulphadiazine / Generic mfg., pyrimethamine / Generic mfg.
    Clinical guideline:  Toxoplasmosis in pregnancy: Practical Management (Pubmed Central) -  Nov 29, 2021   
    If fetal infection is diagnosed by PCR on amniotic fluid, therapy with P-S should be initiated as early as possible or continued in order reduce the risk of damage to the brain or eyes. Further research is required to validate new approaches to preventing congenital toxoplasmosis.
  • ||||||||||  leuprorelin depot / Generic mfg., azacitidine / Generic mfg., docetaxel / Generic mfg.
    Clinical, Journal:  Patient Safety and Satisfaction in Home Chemotherapy. (Pubmed Central) -  Nov 29, 2021   
    All patients reported feeling just as safe as in the hospital. Our results contribute to the feasibility and safety of home chemotherapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, P2 data, Journal:  Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: A Phase II Trial. (Pubmed Central) -  Nov 29, 2021   
    FOLFOXIRI plus targeted agent-based induction chemotherapy and intensified CRT before surgery showed promising clinical activity and was well tolerated in locally advanced rectal cancer patients. This phase II trial provides a strong rationale for phase III studies.
  • ||||||||||  dexamethasone / Generic mfg., methotrexate IV / Generic mfg., methotrexate / Generic mfg.
    A CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION () -  Nov 27, 2021 - Abstract #EHOC2021EHOC_4;    
    No additional treatment was given, except alkaline hydration and calcium folinate, when the findings were observed...Our case stated that he went to the sea two weeks ago and that the bullae secondary to the sunburn that developed afterwards peeled off after they burst. In conclusion, patients with a history of recent generalized sunburn should have their methotrexate delayed to avoid this complication.
  • ||||||||||  methotrexate IV / Generic mfg.
    Hemosorption with HA-230 adsorber in children with cancer in case of Delayed Methotrexate clearance after High Dose Methotrexate Therapy ([VIRTUAL]) -  Nov 25, 2021 - Abstract #Euroanaesthesia2021Euroanaesthesia_1144;    
    Materials and Methods : When conventional therapy (intravenous hydration, leucovorin (FA) rescue) was not effective, the patients (n=7: six of them with acute lymphoblastic leucosis, one with Osteogenic sarcoma) were transferred to the PICU for intensive therapy and hemosorption procedure... Based on our Results , single hemoadsorption procedure with the HA-230 adsorber in case of DMC was safe and well-tolerated in a pediatric patients and would significantly improve the patient’s condition.Further studies needs to demonstrate its safety and efficacy in a large number of pediatric patients
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  Impact of UGT1A1 Genotype on the Efficacy and Safety of Irinotecan-based Chemotherapy in Metastatic Colorectal Cancer. (Pubmed Central) -  Nov 25, 2021   
    The median OS in the mXELIRI and FOLFIRI arms was 18.1 vs. 14.3 months (HR 0.80; 95% CI 0.62-1.03) in the WT group, 16.3 vs. 18.3 months (HR 1.04; 95% CI 0.79-1.36) in the SH group, and 13.0 vs. 9.1 months (HR 0.71; 95% CI 0.39-1.31) in the DHH group, respectively. mXELIRI with or without bevacizumab could be a standard second-line chemotherapy in terms of efficacy and safety regardless of the UGT1A1 genotype.
  • ||||||||||  methotrexate IV / Generic mfg.
    Safety and Effectiveness of a Pharmacist-Driven High-Dose Methotrexate Monitoring Protocol at an Academic Medical Center () -  Nov 24, 2021 - Abstract #ASH2021ASH_6544;    
    The implementation of a pharmacist-driven HD-MTX monitoring protocol improved optimal timing of MTX serum concentrations, resulted in a statistically significant improvement in the rate of appropriate leucovorin dose escalations, and led to enhanced detection of drug interactions. These findings demonstrate the important role pharmacists can play in dosing and monitoring high-risk regimens.